2019-001453-10: A Low-Interventional Study Documenting the Efficacy, Health-Related Quality of Life, and Safety of Standard-Of-Care Treatment with Eculizumab or Treatment with Ravulizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria Un estudio de baja intervención que documenta la eficacia, la calidad de vida relacionada con la salud y la seguridad del tratamiento se referencia con eculizumab o el tratamiento con ravulizumab en pacientes con hemoglobinuria nocturna paroxística |
|
|
| Ongoing | 4 | 200 | Europe | ECULIZUMAB, Ultomiris, Concentrate for solution for infusion, Soliris 300, ULTOMIRIS | Roche Farma S. A. U. que realiza el ensayo en España y que actua como representante F.Hoffmann-La Roche Ltd, F. Hoffman-La Roche Ltd., Chugai Pharmaceutical Co. Ltd | Paroxysmal nocturnal hemoglobinuria (PNH) that is treated with either eculizumab or ravulizumab as per local label Hemoglobinuria paroxística nocturna (HPN) que se trata con eculizumab o ravulizumab según la etiqueta local, PNH is a rare, acquired life-threatening disease, characterized by presence of impaired red blood cells that are easily destroyed, leading to hemoglobin in the urine and anemia as main manifestations HPN es enfermedad rara, adqui q pone en peligro la vida, por la presencia de glóbu rojos deteriorados q se destruyen fácil, lo q lleva a la hemoglobina en orina y anemia como manifestaciones ppales, Diseases [C] - Blood and lymphatic diseases [C15] | | | | |
2019-001619-21: OPTIMIZATION OF MAINTENANCE DOSE WITH ECULIZUMAB ACCORDING TO WEIGHT IN PATIENTS WITH ATYPIC HAEMOLITHIC URINE MUSCLE SYNDROME OPTIMIZACIÓN DE LA DOSIS DE MANTENIMIENTO CON ECULIZUMAB SEGÚN EL PESO EN PACIENTES CON SÍNDROME HEMOLÍTICO URÉMICO ATÍPICO |
|
|
| Not yet recruiting | 4 | 10 | Europe | Solution for infusion, SOLIRIS | HOSPITAL UNIVERSITARI DE BELLVITGE- IDIBELL, HOSPITAL UNIVERSITARI DE BELLVITGE-IDIBELL | ATYPICAL HEMOLYTIC UREMIC SYNDROME SÍNDROME HEMOLÍTICO URÉMICO ATÍPICO, ATYPICAL HEMOLYTIC UREMIC SYNDROME SÍNDROME HEMOLÍTICO URÉMICO ATÍPICO, Not possible to specify | | | | |
2019-003440-74: Phase 4, Single-Arm Study of Ravulizumab in Adult Participants with Paroxysmal Nocturnal Hemoglobinuria Currently Treated with High-Dose Eculizumab |
|
|
| Not yet recruiting | 4 | 20 | Europe | ULTOMIRIS, ALXN1210, Concentrate for solution for infusion, ULTOMIRIS | Alexion Pharmaceuticals Inc., Alexion Pharmaceuticals, Inc. | Paroxysmal nocturnal hemoglobinuria (PNH), Paroxysmal nocturnal hemoglobinuria (PNH), Diseases [C] - Blood and lymphatic diseases [C15] | | | | |
